Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 6 records per page: next > | last >>
pages: 1 2 3 4 5 6 presentations: 1 to 25 of 134
Plenary Session 1: New Targets in Angiogenesis
Overview
Dr. Lee M. Ellis
UT M. D. Anderson Cancer Center, Houston, TX
from 2005 Molecular Targets and Cancer Therapeutics conference on November 15, 2005 10:30 AM-12:30 PM
Plenary Session 1: New Targets in Angiogenesis
Semaphorins and Neuropilins Are Regulators of Tumor Angiogenesis
Dr. Michael Klagsbrun
Children's Hospital, Boston, MA
from 2005 Molecular Targets and Cancer Therapeutics conference on November 15, 2005 10:30 AM-12:30 PM
Plenary Session 1: New Targets in Angiogenesis
Notch Signaling in Angiogenesis and Melanoma Progression
Dr. Meenhard Herlyn
The Wistar Institute, Philadelphia, PA
from 2005 Molecular Targets and Cancer Therapeutics conference on November 15, 2005 10:30 AM-12:30 PM
Plenary Session 1: New Targets in Angiogenesis
Suppression of Angiogenesis and Tumor Growth by Selective Inhibition of Angiopoietin-2
Dr. Jonathan D. Oliner
Amgen, Thousand Oaks, CA
from 2005 Molecular Targets and Cancer Therapeutics conference on November 15, 2005 10:30 AM-12:30 PM
Plenary Session 1: New Targets in Angiogenesis
Integrin alpha-4 beta-1 as a Novel Tumor Molecular Target
Dr. Judith A. Varner
Moores UCSD Cancer Center, La Jolla, CA
from 2005 Molecular Targets and Cancer Therapeutics conference on November 15, 2005 10:30 AM-12:30 PM
Plenary Session 2: Identifying Molecular Targets for Cancer Prevention
Identifying Molecular Targets for Cancer Prevention: Overview
Dr. Eva Szabo
National Cancer Institute, Bethesda, MD
from 2005 Molecular Targets and Cancer Therapeutics conference on November 15, 2005 2:30 PM-4:30 PM
Plenary Session 2: Identifying Molecular Targets for Cancer Prevention
Aromatase and ER as Targets for Prevention in Breast Cancer
Dr. Mitchell Dowsett
Royal Marsden Hospital, London, England
from 2005 Molecular Targets and Cancer Therapeutics conference on November 15, 2005 2:30 PM-4:30 PM
Plenary Session 3: Targeted Molecular Imaging
Overview
Dr. Sanjiv Sam Gambhir
Stanford University, Stanford, CA
from 2005 Molecular Targets and Cancer Therapeutics conference on November 16, 2005 8:00 AM-10:00 AM
Plenary Session 3: Targeted Molecular Imaging
Imaging and Targeted Therapy: Using PET in Clinical Trials and Clinical Practice
Dr. David A. Mankoff
University of Washington, Seattle, WA
from 2005 Molecular Targets and Cancer Therapeutics conference on November 16, 2005 8:00 AM-10:00 AM
Plenary Session 3: Targeted Molecular Imaging
Functional Molecular Imaging to Predict and Monitor Response to Targeted Therapy
Dr. Robert J. Gillies
Arizona Cancer Center, Tucson, AZ
from 2005 Molecular Targets and Cancer Therapeutics conference on November 16, 2005 8:00 AM-10:00 AM
Plenary Session 4: Optimizing Therapies for Inhibiting Kinase Receptors
Update on HER2 Directed Therapy
Dr. Dennis J. Slamon
UCLA School of Medicine, Los Angeles, CA
from 2005 Molecular Targets and Cancer Therapeutics conference on November 16, 2005 10:30 AM-12:30 PM
Plenary Session 4: Optimizing Therapies for Inhibiting Kinase Receptors
Update on the Epidermal Growth Factor Receptor Targeting
Dr. José Baselga
Vall d'Hebron University Hospital, Barcelona, Spain
from 2005 Molecular Targets and Cancer Therapeutics conference on November 16, 2005 10:30 AM-12:30 PM
Plenary Session 4: Optimizing Therapies for Inhibiting Kinase Receptors
Disrupting IGF Receptor Signaling as a Cancer Therapy
Dr. Douglas Yee
University of Minnesota, Minneapolis, MN
from 2005 Molecular Targets and Cancer Therapeutics conference on November 16, 2005 10:30 AM-12:30 PM
Concurrent Session 3: Nanotechnology and Drug Development
Tumor-Specific Nanodelivery Systems: Expanding the Potential for Cancer Therapy and Diagnosis
Dr. Esther Chang
Georgetown University, Washington, DC
from 2005 Molecular Targets and Cancer Therapeutics conference on November 16, 2005 2:30 PM-4:30 PM
Concurrent Session 3: Nanotechnology and Drug Development
Targeted Nanoparticle Beacons for Quantification of Molecular Epitopes and Drug Delivery
Dr. Samuel A. Wickline
Washington University, St. Louis, MO
from 2005 Molecular Targets and Cancer Therapeutics conference on November 16, 2005 2:30 PM-4:30 PM
Plenary Session 5: Apoptosis Pathway Targeting Agents
Apoptosis-based Therapies for Cancer
Dr. John C. Reed
The Burnham Institute, La Jolla, CA
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 8:00 AM-10:00 AM
Plenary Session 5: Apoptosis Pathway Targeting Agents
Human Recombinant TRAIL/Apo2L and Agonistic Monoclonal Antibodies to TRAIL Death Receptors from the Laboratory to the Clinic
Dr. E. G. Elisabeth de Vries
University Hospital, Groningen, The Netherlands
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 8:00 AM-10:00 AM
Plenary Session 5: Apoptosis Pathway Targeting Agents
Developing Chemotherapeutics that Target Mitochondria
Dr. Craig B. Thompson
University of Pennsylvania, Philadelphia, PA
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 8:00 AM-10:00 AM
Plenary Session 5: Apoptosis Pathway Targeting Agents
The IAP Proteins and the XAF1 Antagonist as Cancer Targets
Dr. Robert Korneluk
University of Ottawa, Ottawa, ON, Canada
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 8:00 AM-10:00 AM
Plenary Session 6: Tumor Immunotherapy
TRAIL Receptor Targeted Therapy
Dr. Donald J. Buchsbaum
University of Alabama, Birmingham, AL
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 10:30 AM-12:30 PM
Plenary Session 6: Tumor Immunotherapy
Recombinant Antibody-based Therapeutics
Dr. Richard H. J. Begent
University College London, London, England
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 10:30 AM-12:30 PM
Concurrent Session 7: Regulatory Aspects of Drug Development: Safety, Efficacy, and Beyond
Development and Regulation of New Drugs in Targeted Subgroups
Dr. Jaap Verweij
Erasmus University Medical Center, Rotterdam, The Netherlands
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 2:30 PM-4:30 PM
Concurrent Session 7: Regulatory Aspects of Drug Development: Safety, Efficacy, and Beyond
The Revised European Guidelines for Anticancer Drug Development
Dr. Patrick Therasse
EORTC Data Center, Brussels, Belgium
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 2:30 PM-4:30 PM
Concurrent Session 7: Regulatory Aspects of Drug Development: Safety, Efficacy, and Beyond
Recent Guidance on Early Drug Development
Dr. Jerry M. Collins
Food & Drug Administration, Rockville, MD
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 2:30 PM-4:30 PM
Concurrent Session 7: Regulatory Aspects of Drug Development: Safety, Efficacy, and Beyond
Report on Workshops Dedicated to Endpoints in Cancer Clinical Trials
Dr. Ramzi N. Dagher
Food & Drug Administration, Rockville, MD
from 2005 Molecular Targets and Cancer Therapeutics conference on November 17, 2005 2:30 PM-4:30 PM
<< first | < prev page: of 6 records per page: next > | last >>
pages: 1 2 3 4 5 6 presentations: 1 to 25 of 134